NCT06624644 2026-04-22
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Phase 2/3 Recruiting
Linnaeus Therapeutics, Inc.
M.D. Anderson Cancer Center
Institute of Oncology Ljubljana
The Netherlands Cancer Institute
University Hospital, Montpellier
CNAO National Center of Oncological Hadrontherapy
CNAO National Center of Oncological Hadrontherapy